Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma
Completed · Phase 2
Conditions studied: Sarcoma
In brief
RATIONALE: Nicotine may stimulate the immune system to kill Kaposi's sarcoma cells. PURPOSE: This phase II trial is studying the side effects and how well the nicotine skin patch works in treating patients with Kaposi's sarcoma.
Key facts
- Study ID
- NCT00295984
- Run by
- National Cancer Institute (NCI)
- People needed
- 24
- Starts
- 2006-03-01
- Expected to finish
- 2006-08-01
- Last updated by the study team
- 2013-06-20
Who can join
Age: 18 and older, up to 78. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.